Relay Therapeutics (RLAY) Return on Capital Employed (2020 - 2026)
Relay Therapeutics (RLAY) reported Return on Capital Employed of 47.0% for Q1 2026, down 103.0% year-over-year from 1566.77% in Q1 2025, and up 3.73% on a QoQ basis from 48.82% in Q4 2025.
Relay Therapeutics (RLAY) has 7 years of Return on Capital Employed data on file, last reported at 47.0% in Q1 2026.
- Quarterly Return on Capital Employed fell 103.0% year-over-year to 47.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 47.0% (down 103.0% YoY) and the FY2025 annual result came in at 42.0%, up 416.0% from the prior year.
- Return on Capital Employed improved to 47.0% in Q1 2026 per RLAY's latest filing, from 48.82% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 27.96% in Q4 2022 and bottomed at 49.05% in Q3 2025.
- The 5-year median for Return on Capital Employed is 44.13% (2023), against an average of 41.67%.
- Peak annual rise in Return on Capital Employed reached 1675 bps in 2022, while the deepest fall reached 3175 bps in 2022.
- Tracing RLAY's Return on Capital Employed over 5 years: stood at 27.96% in 2022, then plunged by 58 bps to 44.13% in 2023, then rose by 1 bps to 43.82% in 2024, then decreased by 11 bps to 48.82% in 2025, then gained by 4 bps to 47.0% in 2026.
- Per Business Quant, the three latest RLAY Return on Capital Employed figures stand at 47.0% (Q1 2026), 48.82% (Q4 2025), and 49.05% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | Relay Therapeutics | 2.53 Bn | 2.53 Bn | - | -47.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.00% |
| Dec 31, 2025 | -48.82% |
| Sep 30, 2025 | -49.05% |
| Jun 30, 2025 | -46.89% |
| Mar 31, 2025 | -45.97% |
| Dec 31, 2024 | -43.82% |
| Sep 30, 2024 | -47.20% |
| Jun 30, 2024 | -46.84% |
| Mar 31, 2024 | -44.96% |
| Dec 31, 2023 | -44.13% |
| Sep 30, 2023 | -40.02% |
| Jun 30, 2023 | -39.43% |
| Mar 31, 2023 | -33.83% |
| Dec 31, 2022 | -27.96% |
| Sep 30, 2022 | -30.72% |
| Jun 30, 2022 | -30.74% |
| Mar 31, 2022 | -41.07% |
| Dec 31, 2021 | -44.71% |
| Sep 30, 2021 | -39.43% |
| Jun 30, 2021 | -33.12% |
| Mar 31, 2021 | -9.32% |
| Dec 31, 2020 | -7.32% |
| Sep 30, 2020 | -21.83% |